GSA Capital Partners LLP decreased its position in shares of iRadimed Corp. (NASDAQ:IRMD) by 72.7% during the second quarter, Holdings Channel reports. The firm owned 9,902 shares of the company’s stock after selling 26,330 shares during the period. GSA Capital Partners LLP owned 0.09% of iRadimed Corp. worth $215,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of the stock. California State Teachers Retirement System raised its stake in shares of iRadimed Corp. by 39.6% in the second quarter. California State Teachers Retirement System now owns 8,484 shares of the company’s stock worth $185,000 after buying an additional 2,405 shares during the period. Bank of New York Mellon Corp raised its stake in shares of iRadimed Corp. by 42.9% in the second quarter. Bank of New York Mellon Corp now owns 22,065 shares of the company’s stock worth $480,000 after buying an additional 6,626 shares during the period. State Street Corp raised its stake in shares of iRadimed Corp. by 18.4% in the first quarter. State Street Corp now owns 31,473 shares of the company’s stock worth $603,000 after buying an additional 4,900 shares during the period. Menta Capital LLC raised its stake in shares of iRadimed Corp. by 18.3% in the first quarter. Menta Capital LLC now owns 33,833 shares of the company’s stock worth $648,000 after buying an additional 5,230 shares during the period. Finally, Emerald Acquisition Ltd. bought a new stake in shares of iRadimed Corp. during the second quarter worth about $1,011,000. 20.74% of the stock is owned by institutional investors.
Shares of iRadimed Corp. (NASDAQ:IRMD) traded down 0.06% during midday trading on Friday, hitting $16.99. 140,008 shares of the company’s stock were exchanged. iRadimed Corp. has a 52 week low of $14.05 and a 52 week high of $33.25. The company has a 50-day moving average of $17.69 and a 200-day moving average of $18.31. The firm has a market cap of $181.32 million, a price-to-earnings ratio of 24.41 and a beta of 1.25.
iRadimed Corp. (NASDAQ:IRMD) last posted its quarterly earnings results on Friday, July 29th. The company reported $0.24 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.03. The business earned $9.90 million during the quarter, compared to the consensus estimate of $9.60 million. iRadimed Corp. had a net margin of 24.52% and a return on equity of 30.52%. iRadimed Corp.’s revenue for the quarter was up 30.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.16 earnings per share. Equities research analysts expect that iRadimed Corp. will post $0.92 EPS for the current fiscal year.
Separately, Zacks Investment Research lowered shares of iRadimed Corp. from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 5th.
In related news, VP Steven M. Nardi sold 2,096 shares of the business’s stock in a transaction that occurred on Tuesday, August 16th. The shares were sold at an average price of $17.11, for a total transaction of $35,862.56. Following the completion of the sale, the vice president now directly owns 1,996 shares of the company’s stock, valued at $34,151.56. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 69.00% of the company’s stock.
About iRadimed Corp.
IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.
Want to see what other hedge funds are holding IRMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iRadimed Corp. (NASDAQ:IRMD).
Receive News & Ratings for iRadimed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.